Literature DB >> 8686499

Regulation of COL1A1 expression in type I collagen producing tissues: identification of a 49 base pair region which is required for transgene expression in bone of transgenic mice.

A Bedalov1, R Salvatori, M Dodig, M S Kronenberg, B Kapural, Z Bogdanovic, B E Kream, C O Woody, S H Clark, K Mack.   

Abstract

Previous deletion studies using a series of COL1A1-CAT fusion genes have indicated that the 625 bp region of the COL1A1 upstream promoter between -2295 and -1670 bp is required for high levels of expression in bone, tendon, and skin of transgenic mice. To further define the important sequences within this region, a new series of deletion constructs extending to -1997, -1794, -1763, and -1719 bp has been analyzed in transgenic mice. Transgene activity, determined by measuring CAT activity in tissue extracts of 6- to 8-day-old transgenic mouse calvariae, remains high for all the new deletion constructs and drops to undetectable levels in calvariae containing the -1670 bp construct. These results indicate that the 49 bp region of the COL1A1 promoter between -1719 and -1670 bp is required for high COL1A1 expression in bone. Although deletion of the same region caused a substantial reduction of promoter activity in tail tendon, the construct extending to -1670 bp is still expressed in this tissue. However, further deletion of the promoter to -944 bp abolished activity in tendon. Gel mobility shift studies identified a protein in calvarial nuclear extracts that is not found in tendon nuclear extracts, which binds within this 49 bp region. Our study has delineated sequences in the COL1A1 promoter required for expression of the COL1A1 gene in high type I collagen-producing tissues, and suggests that different cis elements control expression of the COL1A1 gene in bone and tendon.

Entities:  

Keywords:  NASA Discipline Cell Biology; Non-NASA Center

Mesh:

Substances:

Year:  1995        PMID: 8686499     DOI: 10.1002/jbmr.5650101004

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

1.  Far upstream regulatory elements enhance position-independent and uterus-specific expression of the murine alpha1(I) collagen promoter in transgenic mice.

Authors:  K Krempen; D Grotkopp; K Hall; A Bache; A Gillan; R A Rippe; D A Brenner; M Breindl
Journal:  Gene Expr       Date:  1999

2.  Correct cell- and differentiation-specific expression of a murine alpha 1 (I) collagen minigene in vitro differentiating embryonal carcinoma cells.

Authors:  K Rhodes; K Hall; K E Lee; H Razzaghi; M Breindl
Journal:  Gene Expr       Date:  1996

Review 3.  Tissue specific and vitamin D responsive gene expression in bone.

Authors:  C White; E Gardiner; J Eisman
Journal:  Mol Biol Rep       Date:  1998-01       Impact factor: 2.316

Review 4.  Sp7 Action in the Skeleton: Its Mode of Action, Functions, and Relevance to Skeletal Diseases.

Authors:  Hironori Hojo; Shinsuke Ohba
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

5.  High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage.

Authors:  Valérie Geoffroy; Michaela Kneissel; Brigitte Fournier; Alan Boyde; Patrick Matthias
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

6.  Sp7/Osterix Is Restricted to Bone-Forming Vertebrates where It Acts as a Dlx Co-factor in Osteoblast Specification.

Authors:  Hironori Hojo; Shinsuke Ohba; Xinjun He; Lick Pui Lai; Andrew P McMahon
Journal:  Dev Cell       Date:  2016-04-28       Impact factor: 12.270

Review 7.  Visual reporters for study of the osteoblast lineage.

Authors:  Emilie Roeder; Brya G Matthews; Ivo Kalajzic
Journal:  Bone       Date:  2016-09-08       Impact factor: 4.398

Review 8.  Identification of the gene-regulatory landscape in skeletal development and potential links to skeletal regeneration.

Authors:  Hironori Hojo; Ung-Il Chung; Shinsuke Ohba
Journal:  Regen Ther       Date:  2017-05-18       Impact factor: 3.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.